The investment company now also works much more closely with the boards of all three companies.
Trevor Brown, chief executive, told Proactive there’s a good chance one (or all) might end up being the future for Braveheart.
Imaging detector specialist Paraytec – a spin–out from York University’s chemistry department – has developed a scientific grade electronic camera chip for pharmaceutical and biopharma companies to use as a research tool.
Its accuracy means the camera can pick out particles in a fluid and even potentially spot bladder cancer cells in urine, an area of significant interest currently.
Potentially, this might save the NHS millions especially as the aim is to shrink the technology down to smartphone size so eventually people will be able to self-test before going to seek further treatment.
Alzheimer’s is another possible area as the camera can spot a biomarker in the blood associated with the brain disease.
Braveheart has 42% stake, but this will be reduced by a £4mln fundraising in July where it did not participate.
“The [July] funds will be used to complete the development programme and conduct the clinical study required to obtain the necessary regulatory approvals and commercialise the test,” said Brown.
Gyrometric – spun out of Nottingham University– is already generating revenues from its rotating shaft, vibration detection software.
Making this information digital enables it to be analysed faster and in much greater detail, which is critical when it comes to protecting large items of capital equipment such as a ship engine.
Icebreakers, for example, have very expensive drive mechanisms. The software developed by Gyrometrics identifies a potential problem very quickly and shuts down the drive enabling it to be remedied on the spot rather having to go to a shipyard.
Some 49 marine systems have already been delivered, with offshore wind (a €27bn market) and nuclear power stations the next targets.
Braveheart owns more than 50% of Gyrometric.
Kirkstall’s organ on a chip technology is used to improve the efficiency of drugs pipelines and to spot the next potential blockbuster drugs.
Seventy universities already use it and interest is now growing from the pharma sector, with eight companies said to be evaluating the technology.
A distribution agreement was set up for the US with Lonza in 2016 and Kirkstall recently raised £2.5mln to support both this agreement and to develop more applications.
Braveheart retains a significant holding in Kirkstall (38%),
Steady income is provided by the wholly-owned subsidiary, Viking Fund Managers.
Viking's main fund management income comes from a contract with the Finance Yorkshire Equity Fund, but it also provides specialist fund management services to other funds that are in 'run-out' mode.
Profits nearly double
The AIM-listed fund manager reported pre-tax profits for the year to March of £1.49mln, up from £0.78mln the previous year, while its cash at bank stood at £1.13mln, from £1.42mln the year before.
The group added that its portfolio had a valuation at the end of its financial year of £2.22mln, up from £862,000 the year before, owing to “considerable operational progress” in its strategic investment and a recent revaluation of its portfolio.